"Erythropoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
| Descriptor ID |
D004921
|
| MeSH Number(s) |
D12.644.276.374.410.240.150 D12.776.395.240.150 D12.776.467.374.410.240.150 D23.529.374.410.240.150
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Erythropoietin".
Below are MeSH descriptors whose meaning is more specific than "Erythropoietin".
This graph shows the total number of publications written about "Erythropoietin" by people in this website by year, and whether "Erythropoietin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 2 | 3 | 5 |
| 1997 | 2 | 2 | 4 |
| 1998 | 3 | 3 | 6 |
| 1999 | 3 | 0 | 3 |
| 2000 | 2 | 1 | 3 |
| 2001 | 1 | 3 | 4 |
| 2002 | 2 | 2 | 4 |
| 2003 | 2 | 6 | 8 |
| 2004 | 4 | 2 | 6 |
| 2005 | 6 | 2 | 8 |
| 2006 | 7 | 2 | 9 |
| 2007 | 10 | 4 | 14 |
| 2008 | 4 | 4 | 8 |
| 2009 | 3 | 3 | 6 |
| 2010 | 5 | 2 | 7 |
| 2011 | 7 | 2 | 9 |
| 2012 | 5 | 1 | 6 |
| 2013 | 4 | 3 | 7 |
| 2014 | 3 | 2 | 5 |
| 2015 | 4 | 0 | 4 |
| 2016 | 2 | 1 | 3 |
| 2017 | 0 | 3 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 4 | 0 | 4 |
| 2021 | 3 | 4 | 7 |
| 2022 | 5 | 0 | 5 |
| 2023 | 2 | 0 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Erythropoietin" by people in Profiles.
-
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024 Sep; 11(9):e646-e658.
-
Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrol Dial Transplant. 2023 09 29; 38(10):2358-2367.
-
Secondary erythrocytosis. Expert Rev Hematol. 2023 04; 16(4):245-251.
-
Risk of seizures in neonates with hypoxic-ischemic encephalopathy receiving hypothermia plus erythropoietin or placebo. Pediatr Res. 2023 07; 94(1):252-259.
-
Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials. Am J Nephrol. 2022; 53(10):701-710.
-
Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022 09; 97(9):1178-1188.
-
Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns. N Engl J Med. 2022 07 14; 387(2):148-159.
-
Preoperative Administration of Erythropoietin for Craniosynostosis Patients Undergoing Cranial Vault Remodeling: Is There a Benefit? Plast Reconstr Surg. 2022 Feb 01; 149(2):356e-357e.
-
Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrol Dial Transplant. 2021 11 09; 36(11):2039-2048.
-
Epidemiologic and Genetic Associations of Erythropoietin With Blood Pressure, Hypertension, and Coronary Artery Disease. Hypertension. 2021 11; 78(5):1555-1566.